scPharmaceuticals Inc. announced that the Company has received positive Type C meeting feedback from the US Food and Drug Administration (FDA) regarding the potential expansion of the FUROSCIX(R) indication to allow for use in New York Heart Association (NYHA) Class IV heart failure patients. FUROSCIX is currently indicated for the treatment of congestion due to fluid overload in adult patients with NYHA Class II and Class III chronic heart failure. The Company also announced the issuance of U.S. patents covering concentrated formulations of furosemide.

This enables the possibility of developing additional furosemide formulations for subcutaneous administration that will provide clinicians with additional dosing flexibility. The Company has completed initial solubility and stability studies on multiple formulations described in the patent properties, has identified potential product candidates, and commenced IND enabling studies. scPharmaceuticals has additional U.S. patent applications pending that cover various methods of use of such or similar formulations of furosemide for treatment of congestion in patients with heart failure and edema in patients with kidney disease.

The Company is also pursuing similar patent protection outside of the United States.